XML 51 R40.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaborative Research, Development and License Agreements - Additional Information (Detail)
1 Months Ended 3 Months Ended 6 Months Ended
Feb. 28, 2018
USD ($)
Installment
Jan. 31, 2018
USD ($)
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Jun. 30, 2018
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Intangible assets, net         $ 16,364,000
Merck, Sharp & Dohme Corp. | Sublicense Agreement          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Aggregate amount payable to acquire intangible assets $ 21,000,000        
Number of installments | Installment 3        
Payment upon obligation $ 7,000,000        
Intangible assets $ 19,800,000        
Intangible assets, net         $ 16,400,000
Merck, Sharp & Dohme Corp. | Sublicense Agreement | Scenario, Forecast          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Payment upon obligation     $ 7,000,000 $ 7,000,000  
Coley Pharmaceutical Group, Inc.          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Agreement termination date         2018-02
Amortization of intangible assets         $ 2,500,000
Coley Pharmaceutical Group, Inc. | Intangible Assets          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Payment for regulatory milestones recorded as intangible asset   $ 2,500,000      
Maximum          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Additional milestone payments eligible to be received based on achievement of certain development and regulatory objectives         $ 100,000,000